A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain

Overview

The purpose of this study is to determine whether dexmedetomidine added to morphine is effective in the treatment of chronic cancer pain.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: February 2015

Detailed Description

We conduct the study in Cukurova University Faculty of Medicine Research Hospital after obtaining ethics committee approval and patient's informed consent. Patients with cancer pain are allocated into two group to receive Patient Controlled Analgesia with morphine or morphine plus dexmedetomidine.

Interventions

  • Drug: Morphine
    • Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
  • Drug: Morphine plus dexmedetomidine
    • Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval

Arms, Groups and Cohorts

  • Active Comparator: Control
    • Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
  • Active Comparator: Morphine plus dexmedetomidine
    • Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval

Clinical Trial Outcome Measures

Primary Measures

  • Morphine consumption (mg)
    • Time Frame: 24 hours
    • cumulative morphine consumption for 24 hours

Secondary Measures

  • Pain score
    • Time Frame: 24 hours
    • visual analog scale to assess pain degree

Participating in This Clinical Trial

Inclusion Criteria

  • patients with chronic cancer pain – between 20-80 years old age Exclusion Criteria:

  • the presence of severe systemic disease(cardiac, pulmonary, hepatic or renal) – psychiatric or neurologic disease – unable to communicate verbally – nausea and vomiting – patient's refusal

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Cukurova University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ersel GULEC, Ersel Gulec – Cukurova University
  • Overall Official(s)
    • Selcuk Gök, M.D, Principal Investigator, Cukurova University

References

Blaudszun G, Lysakowski C, Elia N, Tramer MR. Effect of perioperative systemic alpha2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2012 Jun;116(6):1312-22. doi: 10.1097/ALN.0b013e31825681cb.

Citations Reporting on Results

Lin TF, Yeh YC, Lin FS, Wang YP, Lin CJ, Sun WZ, Fan SZ. Effect of combining dexmedetomidine and morphine for intravenous patient-controlled analgesia. Br J Anaesth. 2009 Jan;102(1):117-22. doi: 10.1093/bja/aen320. Epub 2008 Nov 5.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.